ResearcherMedical College of WisconsinActive in the last 2 years
Gareth Pollin
Matched on ORCID iD 0000-0002-2787-6673; OpenAlex author ID A5022569050. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2024: 1 paper · 2025: none · 2026: 2 papers
Papers 3
- PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. First author DOI 10.3389/fcell.2026.1748541↗
- Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. Co-author DOI 10.3390/epigenomes10010019↗
- Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer Co-author DOI 10.21037/jgo-24-326↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael T. Zimmermann · 3 shared papers, 2024–2026 · strength 0.87
- Paper Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. DOI 10.3390/epigenomes10010019↗
- Paper PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. DOI 10.3389/fcell.2026.1748541↗
- Paper Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer DOI 10.21037/jgo-24-326↗
- Raul A. Urrutia · 3 shared papers, 2024–2026 · strength 0.87
- Paper Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. DOI 10.3390/epigenomes10010019↗
- Paper PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. DOI 10.3389/fcell.2026.1748541↗
- Paper Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer DOI 10.21037/jgo-24-326↗
- Gwen Alyce Lomberk · 3 shared papers, 2024–2026 · strength 0.87
- Paper Mutant KRAS Heterogeneity Shapes Nuclear Architecture During Pancreatic Cancer Initiation. DOI 10.3390/epigenomes10010019↗
- Paper PRMT5 inhibition triggers functional ATM deficiency and sensitizes pancreatic cancer to CHK1 blockade. DOI 10.3389/fcell.2026.1748541↗
- Paper Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer DOI 10.21037/jgo-24-326↗
- Juan Iovanna · 1 shared paper, 2026 · strength 0.30
- Madeline M. Dzikowski · 1 shared paper, 2026 · strength 0.29
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.